CB Pharma Acquisition Corp., of Burlington, Mass., founded by Coronado Biosciences Inc., said it has completed the sale of an additional 200,000 units related to the 45-day overallotment option granted to the underwriters in its public offering to purchase up to an additional 600,000 units. The company also completed a simultaneous private placement of an additional 1,000 private placement units to Earlybirdcapital Inc. The gross proceeds of the public offering and private placements of approximately $42.9 million were placed in trust.
Dynavax Technologies Corp., of Berkeley, Calif., said it entered into a credit facility with Hercules Technology Growth Capital, Inc. for up to $40 million of total funding. The first tranche of $10 million was drawn on closing and the company will have access to an additional $30 million in 2015, at their option, if it achieves certain milestones relating to an ongoing phase III study of Heplisav-B (HBV-23).